Advertisement

Topics

Merck Presents Promising Phase II Trial Results for OA Drug

10:38 EST 8 Nov 2017 | Drug Discovery Development

Late-breaking presentation at the 2017 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting (ACR/ARHP) provides data on cartilage thickness in patients with knee osteoarthritis.
Contributed Author: 
Merck KGaA
Topics: 

Original Article: Merck Presents Promising Phase II Trial Results for OA Drug

NEXT ARTICLE

More From BioPortfolio on "Merck Presents Promising Phase II Trial Results for OA Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Joint Disorders
A joint is where two or more bones come together, like the knee, hip, elbow, or shoulder. Joints can be damaged by many types of injuries or diseases, including Arthritis - inflammation of a joint causes pain, stiffness, and swelling with ...